RE:RE:RE:Second Reading on the UK Drug Bill in the House of CommonsOne more guide down and the debt to ebitda rise will make this untouchable for even the bravest of folk. Is there a debt to ebitda ratio where the debt holders can move in on the assets? Wait, don't tell me, i do want to keep this a suspenseful ride to zero!
LaticelnExile wrote: Craigbad wrote: Could be an early Christmas present! The "growth" was supposed to come from the Uk. This could be the nail in the coffin. Government in the Uk works quick, the loophole was just exposed a short time ago. They better sell this dumpster fire quick before private equity finds out about the upcoming price controls if they thought brexit was a bump! Lol
LaticelnExile wrote: ... will be on October 5, 2016!
Who on this board said something about 2017 ?
Oops. I meant Monday October 10, (not October 5th), 2016. But it does looks like its a present that will keep on giving before Christmas! AMCo has gamed the system by having their branded drug approved by the NHS but then later asking the NHS to strip the brand name from the drug thus making it generic. Concordia then even calls it a "pipeline launch" (which is why investors never get to hear the names of their new drug launches, and just hear "we have launched 13 in the quarter and we can't divulge the names because of prioprietary reasons...." (How doped do they think investors are? Aren't the reps selling these "secret" drugs? Aren't they in the NHS tariff books if anyone wants to check? What a lame excuse). Once they have the brand name stripped to make it a generic AMCo can raise prices on the drugs as much as they want. The NHS assumes that competition will keep generic prices low. However in AMCo's case, where their drugs have such a small market, they have been able to leverage their pure play generic capabilities. It really was a brilliant scheme. Except for the fact that they were caught and now the NHS knows their game.